Novotech Releases Comprehensive Report on Oncolytic Virus Therapy

Explore the latest insights into global clinical trial trends, innovations, and strategies shaping the future of oncolytic virus therapy.

SYDNEY--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, has released its latest report, Oncolytic Virus Therapy: Global Clinical Trial Landscape 2024. This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.

Oncolytic virus therapies utilize genetically modified or naturally occurring viruses to selectively target tumor cells and stimulate immune responses. This dual mechanism is creating new possibilities in oncology and other therapeutic areas.

Key Highlights:

• Global Trial Landscape: Asia-Pacific leads with 40% of OVT clinical trials, followed closely by North America and Europe, reflecting a global focus on advancing these therapies.
  
  
• Pipeline Insights: Solid tumors dominate OVT research, with trials targeting cancers such as melanoma, glioblastoma, and pancreatic cancer.
  
  
• Innovative Delivery Systems: Advances like nanoparticle systems and cell-based carriers address key challenges in targeting and delivery.
  
  
• Combination Therapies: Integration with immune checkpoint inhibitors, CAR-T therapies, and chemotherapy is enhancing the efficacy and scope of OVT.
  
  
• Regulatory Overview: Provides guidance on navigating complex global regulatory pathways, including insights into fast-tracking approvals.

This complimentary report offers biotech and pharmaceutical companies, data-driven analysis to navigate the complexities of clinical trials and regulatory frameworks in oncolytic virus therapy.

Download the Report

About Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com